ANN ARBOR—Fifth Eye, a medical software startup developing real-time clinical analytics, announced that the U.S. Food and Drug Administration has provided clearance to market its second generation clinical decision support software, the AHI System, to hospitals in the United States. AHI, pronounced AH-hee, stands for Analytic for Hemodynamic Instability. Hemodynamic instability is a condition in which
ANN ARBOR—Clinical analytics startup Fifth Eye Inc. announced that the U.S. Food and Drug Administration has granted its “de novo” classification to Fifth Eye’s Analytic for Hemodynamic Instability (AHI). According to the FDA’s website, “De novo” classification means FDA officials believe the new software has “reasonable assurance of safety and effectiveness for the intended use.” Fifth Eye’s
ANN ARBOR - Fifth Eye Inc., a digital health predictive analytics company, has received a $2.36 million investment from Invest Michigan, Biosciences Research and Commercialization Center, and 33 private angel investors. Fifth Eye develops real-time predictive analytic patient data software to give doctors and nurses a heads up hours in advance about impending trouble ranging
